By Stephen Levin
Last year's American Heart Association meeting included a presentation on niche devices in interventional cardiology, which featured leading interventionalists discussing...
The ideal treatment for coronary artery disease is to remove the obstructing plaque, for which several de-bulking technologies, including atherectomy, were developed. The stent revolution of the mid-1990s provided an easier-to-use therapy with more consistent outcomes, relegating de-bulking tools to niche technologies. Physician/entrepreneur John Simpson, who developed the initial atherectomy technology at Devices for Vascular Intervention, remains committed to the principle that it is better to remove plaque than stent it. He believes the next-generation atherectomy device developed at his new company, Fox Hollow, will be a viable treatment option to compete with stenting, including the new generation of drug-eluting stents. Fox Hollow recognizes the need to fight the atherectomy adoption battle on both the ease-of-use and the clinical outcomes fronts, with the latter being particularly important as interventionalists look increasingly to clinical trials in making their product choices. But drug-eluting stent proponents don't believe it is possible to achieve comparable outcomes.
By Stephen Levin
Last year's American Heart Association meeting included a presentation on niche devices in interventional cardiology, which featured leading interventionalists discussing...
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.